Background {#Sec1}
==========

Health technology assessment (HTA) has become an important tool to support health policy decisions in many countries \[[@CR1]\]. The majority of HTAs still focus on clinical medicine, in particular on pharmaceuticals. HTAs of public health interventions (PHIs) are still rare \[[@CR2]\]. A 2010 survey conducted in five countries found that three in four HTAs covered a clinical topic, but only 5% of HTAs were on a public health issue \[[@CR3]\].

HTA of PHIs poses some challenges \[[@CR4]\]. PHIs tend to be highly complex due to varying intervention components (e.g. educational, psychological, or sociological), participants, contextual factors and multiple causal pathways \[[@CR5]\]. Randomized controlled trials (RCTs) are often the most important data source for effectiveness in HTAs. However, RCTs on PHIs are often difficult to conduct because of ethical or feasibility issues. This leads to a lack of RCTs on PHIs \[[@CR6]\]. HTAs on PHIs often have to rely on other study designs, in particular quasi-experimental designs such as controlled before-after studies or interrupted time series that are more prone to cofounding than RCTs. Because of these challenges, the standard tools for HTA (e.g. electronic databases, risk of bias assessment) are often not fit for purpose and may not even be applicable at all for PHIs \[[@CR7], [@CR8]\].

HTA agencies prepare HTAs on PHIs and consequently have to deal with these challenges. Only few HTA agencies have standardized, formalized methods specific for HTAs on PHIs, and the few suggested approaches are heterogeneous \[[@CR8]\].

There is no systematic analysis on the methods applied in HTAs on PHIs. The aim of this study is to provide an overview of the methodological characteristics and to compare the assessment methods that have been applied in HTAs of PHIs. More specifically, our purpose is to get deeper insights into the approaches that are actually applied to deal with the challenges arising in HTAs of PHIs.

Methods/design {#Sec2}
==============

We used the PRISMA-P checklist \[[@CR9]\] for guiding the preparation of this protocol. Not all items of the checklist were applicable due to the nature of this work (see Additional file [1](#MOESM1){ref-type="media"}).

As no outcome of direct patient or clinical relevance is assessed in this work, the protocol could not be registered in PROSPERO.

Searches {#Sec3}
--------

We will systematically search the webpages of the international umbrella organizations for systematic reviews and national HTA agencies. We will identify the HTA agencies by using the member lists of the following HTA umbrella organizations: the International Network of Agencies for Health Technology Assessment (INAHTA), Health Technology Assessment International (HTAi) and the European Network for Health Technology Assessment (EUnetHTA; 06/2016: 115 organizations). Because PHIs are very diverse, numerous search terms can be potentially relevant. Therefore, we will not use search terms for searching the webpages but screen the full lists of all published HTAs. One reviewer will perform the searches. References will be managed with EndNote X7.

Inclusion criteria {#Sec4}
------------------

Two reviewers will independently screen potentially relevant reports according to the following inclusion criteria:Full HTA report as defined by INAHTA (see details below) \[[@CR10]\]Assessment of a public health interventionPublication date: 2012 to 2016Language: English, German, Spanish and French

We will apply the following key aspects of the INAHTA definition of full HTA reports for study selection \[[@CR10]\]:○ *Always*• Evaluate safety and effectiveness issues.• Determine the cost-effectiveness of the technology, e.g. through economic modelling (when it is appropriate).○ *Always* conduct a comprehensive systematic literature review or a systematic review of high-level evidence.○ *Always* critically appraise the quality of the evidence base.○ *Optionally* address ethical, social and legal considerations.

We will exclude all literature review-based HTAs using accelerated (e.g. rapid reviews) or abbreviated HTA/systematic review methods, overviews of reviews (or umbrella reviews), scoping reviews, mini-HTAs, etc. \[[@CR10], [@CR11]\]. We will exclude protocols for HTAs because we are primarily interested in the actual application of methods for dealing with the challenges when evaluating a PHI.

Public health is a broad discipline and not homogeneously defined in the literature. In this review, we will consider only population-based interventions on health promotion and interventions for primary prevention of chronic (e.g. cardiovascular diseases, diabetes and non-communicable \[e.g. injury\]) or infectious disease to ensure consistent study selection \[[@CR12]\]. We will exclude HTAs on screening and vaccination because these require special evaluation methods (e.g. diagnostic accuracy studies, modelling) \[[@CR13]\].

As our intention is to provide an overview of the currently applied approaches, we will include only reports published in the last 5 years (2012--2016). In case that a HTA agency published more than ten relevant HTAs within the past 5 years, we will randomly select ten reports of this agency to avoid overrepresentation of one HTA agency. We will include a maximum of 100 HTAs in the analysis. In the case that this threshold is exceeded, we will adapt the maximum number of HTAs per agency accordingly. We will include at least one report for each agency, even when the threshold of 100 HTAs will be exceeded.

One reviewer will screen all abstracts and full texts, and a second reviewer will screen the excluded records only (liberal acceleration).

A flow diagram will illustrate the selection process, and we will provide a list of the excluded HTA reports to ensure transparency of the selection process.

Data extraction {#Sec5}
---------------

We will prepare standardized tables for data extraction. We will pilot the data extraction tables before the conduction of the review with HTAs published before 2012. Two reviewers will independently extract the data.

For all HTA reports, we will extract data on (i) population and (ii) intervention characteristics, (iii) country of origin, (iv) review planning, (v) definition of the research question and (vi) the development of the theoretical framework/theory of change.

Furthermore, we will extract detailed information on the applied methods for each domain (effectiveness, safety and economic as well as on social, cultural, ethical and legal aspects).

### Health (effectiveness/safety) aspects {#Sec6}

If the assessment is based on a systematic review, then we will extract data on the following issues:Included study designs (e.g. interrupted time series)Search strategy (electronic databases and additional searches)Data extraction (items, method, involved reviewers)Risk of bias/quality assessment (tool, method, involved reviewers)Considering context/setting in the assessmentAssessment of applicability/generalizability (tool, method, involved reviewers)Assessment of intervention integrityAssessment of sustainabilityAssessment of heterogeneityIntegration qualitative and quantitative studiesInformation on subgroups (see below)

Many different primary study types (e.g. surveys) or synthesis methods (e.g. rapid reviews) can be used in addition to full systematic reviews to assess the effectiveness of (complex) health interventions \[[@CR14]--[@CR16]\]. We will also extract data on features of other synthesis methods than "traditional" systematic reviews (e.g. realist reviews) and on other assessment methods such as trials, surveys and expert reviews.

### Economic aspects {#Sec7}

Also, the economic evaluation of PHIs presents some additional methodological challenges. Methodological challenges refer to the complexity of the intervention, the choice of comparators and the consideration of multiple or intermediate outcomes. These issues often require complex modelling techniques.

In the economic domain, we will consider whether a primary economic evaluation and/or a systematic literature search of existing economic evaluations is performed.

For primary economic evaluations, we will extract the following information:Type of economic evaluationChoice of comparatorsTime/analysis horizonPerspective of analysisCosts considered (e.g. direct medical costs, indirect costs)Sources/measurement of costsValuating resources (pricing)Sources/measurement of outcomesValuation of outcomes (e.g. time-trade-off)DiscountingModelling approach (e.g. Markov model, system dynamics)Sensitivity analysisPresentation of results

For systematic reviews of economic evaluations, we will extract:Scope of the systematic review (exclusively a systematic review of economic evaluations or systematic review to inform primary economic evaluation)Included economic evaluation typesLiterature search strategy (databases, additional sources, involved reviewers)Data extraction (items, method)Assessment of methodological quality (tool, method)Assessment of generalizability/transferability/applicability (tools, procedure)Presentation of cost data (e.g. currency conversion)Method for data synthesis (narrative, graphical, meta-analysis)

Furthermore, we will consider if the results of the economic evaluation can explicitly influence the final decision (e.g. through a cost-effectiveness threshold).

We will extract whether the HTA includes a budged impact analysis but no details on the methods for the budget impact analysis.

### Social and cultural aspects {#Sec8}

If social and cultural aspects are considered, then we will extract information on \[[@CR17]\]:The social and cultural aspects addressedTheoretical framework chosenAssessment method chosenQuantitativeQualitativeMixed methodsLiterature review of qualitative and/or quantitative studiesExplicit implications for the HTA

### Legal aspects {#Sec9}

Information on the approaches for considering legal aspects will be extracted. We will consider the following legal aspects \[[@CR15]\]:Informed consentAlternative forms of consentPrivacy and data protectionMarket authorization of medical devices and medicinal productsClinical trialsIntellectual propertiesReimbursement in public health care systemsSpecial medical fields

There is no standardized approach for incorporating legal aspects \[[@CR18]\]. Therefore, we will further specify the data extraction for legal aspects after the literature screening.

### Ethical aspects {#Sec10}

If possible, we will extract information on:The ethical issues addressedThe normative framework chosenThe methods employed for arriving at recommendationsExplicit implications for the HTA

As this part of systematic reviews is largely underdeveloped and no clear standards are formulated, we are not able to predict what approaches were chosen \[[@CR19]\]. We expect considerable variation in the understanding of ethical aspects and the methods employed. Therefore, it might become necessary to adapt this list after a first screening of the literature (but before in-depth analysis of the publications identified).

Risk of bias assessment/quality {#Sec11}
-------------------------------

We will not assess the quality of HTA reports because we focus on exploring methodological features of HTAs on PHIs. We will include only HTAs that perform a systematic literature search and perform a critical appraisal of included studies, which can be considered as minimal requirements for HTA quality.

Data synthesis {#Sec12}
--------------

We will tabulate data for each domain. The information will be synthesized in a structured narrative way for the respective domain and also across domains.

Statistics {#Sec13}
----------

We will describe dichotomous and nominal variables using absolute numbers and percentages. We will prepare means and standard deviations for metric variables. For ordinal and skewed metric variables, we will calculate median and ranges.

All analyses will be performed using SPSS 23 software.

Analysis of subgroups {#Sec14}
---------------------

We plan to perform two subgroup analyses. First, we will consider HTAs on health promotion separately from HTAs on primary prevention. Second, HTAs will be analysed according to the different health care systems (e.g. Beveridge model, Bismarck model, National Health Insurance model), target audiences (e.g. physicians, policy decision makers) and evaluation level (e.g. hospital/primary care, region, national) to identify justified methodological differences (e.g. perspective of analysis, assessment of applicability). We will code the subgroups based on description of the intervention, country of origin, setting and perspective of the analysis.

Discussion {#Sec15}
==========

HTA is a tool to support policy decisions \[[@CR20]\]. A comprehensive and transparent assessment is in particular important in the field of public health because the decision process often involves a large variety of stakeholders.

The analysis will provide a comprehensive overview of methods applied in HTAs on PHIs. We will get insights into promising approaches for dealing with the challenges when evaluating PHIs. Furthermore, our work might identify important research gaps. This analysis can stipulate further development and harmonization of methods for HTAs on PHIs. An advancement of the methods can contribute to a higher degree of acceptance of HTAs on PHIs by policy makers and improved policy decision-making based on the principles of evidence-based medicine.

We are aware that especially in the evaluation of a PHI, social and ethical considerations should be addressed. Social and cultural norms influence how people perceive a health issue and accept an intervention and its implementation \[[@CR15]\]. These might cause differences in effectiveness between groups. To avoid the exclusion of a majority of HTAs, we decided to include also HTAs evaluating only effectiveness/safety and economic aspects.

Our work has some limitations. First, our focus on health promotion and interventions for primary prevention, as public health covers a broader field encompassing environmental, behavioural and clinical interventions for secondary and tertiary prevention. This decision was made because we want a sample of HTAs that represents the specific characteristics of PHIs and allows unambiguous differentiation from other medical fields. While we have not found another satisfying way that clearly distinguishes PHIs from other interventions, we presume that our results are also applicable to other PHIs. Second, the results of our analysis might be biased toward European and North American countries because of our language restrictions. A third limitation is that we will not arrive at a representative sample of HTAs because of our strict inclusion criteria (full HTAs, only literature-based HTAs). This decision was made because we deduced our inclusion criteria from a previous work that analysed the methods in manuals for HTAs on PHIs \[[@CR8]\]. Thus, this work will provide only an extract of "state of the art" methods. We acknowledge that these methods are not always feasible because of lack of resources to perform an in-depth analysis or lack of appropriate literature.

In a future project, we will widen our scope and also consider HTAs that only use accelerate review methods (e.g. rapid reviews) or primary data analysis (e.g. quasi-experimental designs, expert surveys).

Additional file
===============

 {#Sec16}
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EUnetHTA

:   European Network for Health Technology Assessment

HTA

:   Health technology assessment

INAHTA

:   International Network of Agencies for Health Technology Assessment

HTAi

:   Health Technology Assessment International

PHI

:   Public health intervention

RCT

:   Randomized controlled trial
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